Immunogenicity and Reactogenicity of a Booster Dose of GSK Bio's DTPa-HBV-IPV/Hib Vaccine

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT00627458

Recruitment Status : Completed

First Posted : March 3, 2008

Results First Posted : June 26, 2017

Last Update Posted : June 6, 2018

Sponsor:

Information provided by (Responsible Party):

GlaxoSmithKline

Study Description

Brief Summary:

The purpose of this booster study is to evaluate, in subjects primed in the primary study 106786, the persistence, at the time of the booster vaccination, of antibodies elicited by the different formulation of DTPa-HBV-IPV/ Hib vaccine (Infanrix Hexa TM). The study will also evaluate the immune response of these subjects to a DTPa-HBV-IPV/Hib booster. This protocol posting deals with the objectives and outcome measures of the booster phase. The objectives and outcomes measures of the primary phase are presented in a separate protocol posting (NCT = 00376779).

Condition or disease	Intervention/treatment	Phase
Acellular Pertussis Diphtheria Poliomyelitis Haemophilus Influenzae Type b Tetanus Hepatitis B	Biological: Infanrix Hexa	Phase 2

Detailed Description:

This protocol posting has been updated in order to comply with the FDA AA, Sep 2007.

Study Design

Layout table for study information

Study Type :	Interventional (Clinical Trial)
Actual Enrollment :	403 participants
Allocation:	Non-Randomized
Intervention Model:	Parallel Assignment
Masking:	None (Open Label)
Primary Purpose:	Prevention
Official Title:	Immunogenicity and Reactogenicity of GSK Biologicals' DTPa-HBV-IPV/Hib Vaccine When Given as a Booster Dose
Study Start Date :	February 1, 2008
Actual Primary Completion Date :	August 18, 2008
Actual Study Completion Date :	August 18, 2008

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Haemophilus Infections Tetanus, Diphtheria, and Pertussis Vaccines Vaccines

Drug Information available for: Boostrix Diphtheria-Tetanus-acellular Pertussis Vaccines

Genetic and Rare Diseases Information Center resources: Whooping Cough Tetanus Poliomyelitis Diphtheria Haemophilus Influenzae Myelitis

U.S. FDA Resources

Arms and Interventions

Arm	Intervention/treatment
Experimental: INFANRIX HEXA PF GROUP Healthy male and female subjects between, and including 16 and 20 months of age at the time of booster vaccination, who were given the preservative-free (PF) formulation of Infanrix Hexa™ in the primary vaccination study 106786, additionally received a single booster dose of Infanrix Hexa™ vaccine, administered intramuscularly into the anterolateral quadrant of the right thigh.	Biological: Infanrix Hexa Vaccine administered as a booster dose at 16-20 months of age Other Name: GSK Biological's combined DTPa-HBV-IPV/Hib vaccine
Experimental: INFANRIX HEXA PC GROUP Healthy male and female subjects between, and including 16 and 20 months of age at the time of booster vaccination, who were given the preservative-containing (PC) formulation of Infanrix Hexa™ in the primary vaccination study 106786, additionally received a single booster dose of Infanrix Hexa™ vaccine, administered intramuscularly into the anterolateral quadrant of the right thigh.	Biological: Infanrix Hexa Vaccine administered as a booster dose at 16-20 months of age Other Name: GSK Biological's combined DTPa-HBV-IPV/Hib vaccine
Active Comparator: CONTROL GROUP Healthy male and female subjects between, and including 16 and 20 months of age at the time of booster vaccination, who were given the licensed formulation of Infanrix Hexa™ in the primary vaccination study 106786, additionally received a single booster dose of Infanrix Hexa™ vaccine, administered intramuscularly into the anterolateral quadrant of the right thigh.	Biological: Infanrix Hexa Vaccine administered as a booster dose at 16-20 months of age Other Name: GSK Biological's combined DTPa-HBV-IPV/Hib vaccine

Outcome Measures

Primary Outcome Measures :

Number of Seroprotected Subjects Against Diphtheria (D) and Tetanus (T) Toxoids [ Time Frame: Before the booster administration (At Month 0) ]
A seroprotected subject was defined as a subject with anti-D and anti-T antibody concentrations greater than or equal to (≥) 0.1 international units per milliliter (IU/mL).
Number of Seroprotected Subjects Against Diphtheria (D) and Tetanus (T) Toxoids [ Time Frame: One month after the booster vaccination (At Month 1) ]
A seroprotected subject was defined as a subject with anti-D and anti-T antibody concentrations greater than or equal to (≥) 0.1 IU/mL.
Number of Seroprotected Subjects Against Hepatitis B Surface Antigen (HBs) [ Time Frame: Before the booster vaccination (At Month 0) ]
A seroprotected subject was defined as a subject with anti-HBs antibody concentrations ≥ 10 milli international units per milliliter (mIU/mL). Also reported are the number of participants with anti-HBs antibody concentrations ≥ 100 mIU/mL.
Number of Seroprotected Subjects Against Hepatitis B Surface Antigen (HBs) [ Time Frame: One month after the booster vaccination (At Month 1) ]
A seroprotected subject was defined as a subject with anti-HBs antibody concentrations ≥ 10 mIU/mL. Also reported are the number of participants with anti-HBs antibody concentrations ≥ 100 mIU/mL.
Number of Seroprotected Subjects Against Poliovirus Type 1, Type 2 and Type 3 [ Time Frame: Before the booster vaccination (At Month 0) ]
A seroprotected subject was defined as a subject with anti-Polio 1, 2 and 3 antibody titers ≥ the value of 8.
Number of Seroprotected Subjects Against Poliovirus Type 1, Type 2 and Type 3 [ Time Frame: One month after the booster vaccination (At Month 1) ]
A seroprotected subject was defined as a subject with anti-Polio 1, 2 and 3 antibody titers ≥ the value of 8.
Number of Seroprotected Subjects Against Pertussis Toxoid (PT), Filamentous Haemagglutinin (FHA) and Pertactin (PRN) [ Time Frame: Before the booster vaccination (At Month 0) ]
A seroprotected subject was defined as a subject with anti-PT, anti-FHA and anti-PRN antibody concentrations ≥ 5 enzyme-linked immunosorbent assay (ELISA) units per milliliter (EL.U/mL).
Number of Seroprotected Subjects Against Pertussis Toxoid (PT), Filamentous Haemagglutinin (FHA) and Pertactin (PRN) [ Time Frame: One month after the booster vaccination (At Month 1) ]
A seroprotected subject was defined as a subject with anti-PT, anti-FHA and anti-PRN antibody concentrations ≥ 5 EL.U/mL.
Number of Seroprotected Subjects Against Polyribosyl-ribitol-phosphate (PRP) [ Time Frame: Before the booster vaccination (At Month 0) ]
A seroprotected subject was defined as a subject with anti-PRP antibody concentrations greater than or equal to (≥) 0.15 micrograms per milliliter (µg/mL). Also reported are the number of participants with anti-PRP antibody concentrations ≥ 1.0 µg/mL.
Number of Seroprotected Subjects Against Polyribosyl-ribitol-phosphate (PRP) [ Time Frame: One month after the booster vaccination (At Month 1) ]
A seroprotected subject was defined as a subject with anti-PRP antibody concentrations ≥ 0.15 µg/mL. Also reported are the number of participants with anti-PRP antibody concentrations ≥ 1.0 µg/mL.
Number of Subjects With a Vaccine Response to PT, FHA and PR [ Time Frame: One month after the booster vaccination (At Month 1) ]
Vaccine response was defined as the appearance of antibodies in subjects who were initially seronegative (S-) [i.e. with concentrations lower than (<) the cut-off value] or at least doubling of pre-vaccination antibody concentrations in subjects who were initially seropositive (S+) [i.e. with concentrations greater than (>) the cut-off value).
Anti-D and Anti-T Antibody Concentrations [ Time Frame: Before the booster vaccination (At Month 0) ]
Antibody concentrations were presented as geometric mean concentrations (GMCs), expressed in IU/mL.
Anti-D and Anti-T Antibody Concentrations [ Time Frame: One month after the booster vaccination (At Month 1) ]
Antibody concentrations were presented as geometric mean concentrations (GMCs), expressed in IU/mL.
Anti-PT, Anti-FHA and Anti-PRN Antibody Concentrations [ Time Frame: Before the booster vaccination (At Month 0) ]
Antibody concentrations were presented as geometric mean concentrations (GMCs), expressed in EL.U/mL.
Anti-PT, Anti-FHA and Anti-PRN Antibody Concentrations [ Time Frame: One month after the booster vaccination (At Month 1) ]
Antibody concentrations were presented as geometric mean concentrations (GMCs), expressed in EL.U/mL.
Anti-HBs Antibody Concentrations [ Time Frame: Before the booster vaccination (At Month 0) ]
Antibody concentrations were presented as geometric mean concentrations (GMCs), expressed in mIU/mL.
Anti-HBs Antibody Concentrations [ Time Frame: One month after the booster vaccination (At Month 1) ]
Antibody concentrations were presented as geometric mean concentrations (GMCs), expressed in mIU/mL.
Anti-poliovirus Type 1, Type 2 and Type 3 Antibody Titers [ Time Frame: Before the booster vaccination (At Month 0) ]
Antibody titers were presented as geometric mean titers (GMTs).
Anti-poliovirus Type 1, Type 2 and Type 3 Antibody Titers [ Time Frame: One month after the booster vaccination (At Month 1) ]
Antibody titers were presented as geometric mean titers (GMTs).
Anti-PRP Antibody Concentrations [ Time Frame: Before the booster vaccination (At Month 0) ]
Antibody concentrations were presented as geometric mean concentrations (GMCs), expressed in micrograms per milliliter (µg/mL).
Anti-PRP Antibody Concentrations [ Time Frame: One month after the booster vaccination (At Month 1) ]
Antibody concentrations were presented as geometric mean concentrations (GMCs), expressed in µg/mL.

Secondary Outcome Measures :

Number of Seroprotected Subjects Against Diphtheria (D) and Tetanus (T) Toxoids [ Time Frame: Before (Month 0) and one month after (Month 1) the booster vaccination ]
A seroprotected subject was defined as a subject with anti-D and anti-T antibody concentrations ≥ 0.1 IU/mL .
Number of Seroprotected Subjects Against Hepatitis B Surface Antigen (HBs) [ Time Frame: Before (Month 0) and one month after (Month 1) the booster vaccination ]
A seroprotected subject was defined as a subject with anti-HBs antibody concentrations ≥ 10 mIU/mL. Also reported are the number of participants with anti-HBs antibody concentrations ≥ 100 mIU/mL.
Number of Seroprotected Subjects Against Poliovirus Type 1, Type 2 and Type 3 [ Time Frame: Before (Month 0) and one month after (Month 1) the booster vaccination ]
A seroprotected subject was defined as a subject with anti-polio 1, 2 and 3 antibody titers ≥ the value of 8.
Number of Seroprotected Subjects Against PT, FHA and PRN [ Time Frame: Before (Month 0) and one month after (Month 1) the booster vaccination ]
A seroprotected subject was defined as a subject with anti-PT, anti-FHA and anti-PRN antibody concentrations ≥ 5 EL.U/mL .
Number of Seroprotected Subjects Against Polyribosyl-ribitol-phosphate (PRP) [ Time Frame: Before (Month 0) and one month after (Month 1) the booster vaccination ]
A seroprotected subject was defined as a subject with anti-PRP antibody concentrations ≥ 0.15 μg/mL. Also reported are the number of participants with anti-PRP antibody concentrations ≥ 1.0 µg/mL.
Anti-D and Anti-T Antibody Concentrations [ Time Frame: Before (Month 0) and one month after (Month 1) the booster vaccination ]
Antibody concentrations were presented as geometric mean concentrations (GMCs), expressed in IU/mL.
Anti-PT, Anti-FHA, Anti-PRN Antibody Concentrations [ Time Frame: Before (Month 0) and one month after (Month 1) the booster vaccination ]
Antibody concentrations were presented as geometric mean concentrations (GMCs), expressed in EL.U/mL.
Anti-HBs Antibody Concentrations [ Time Frame: Before (Month 0) and one month after (Month 1) the booster vaccination ]
Antibody concentrations were presented as geometric mean concentrations (GMCs), expressed in mIU/mL.
Anti-poliovirus Type 1, 2 and 3 Antibody Titers [ Time Frame: Before (Month 0) and one month after (Month 1) the booster vaccination ]
Antibody titers were presented as geometric mean titers (GMTs).
Anti-PRP Antibody Concentrations [ Time Frame: Before (Month 0) and one month after (Month 1) the booster vaccination ]
Antibody concentrations were presented as geometric mean concentrations (GMCs), expressed in µg/mL.
Number of Subjects With a Vaccine Response to PT, FHA and PR [ Time Frame: One month after the booster dose (At Month 1) ]
Vaccine response was defined as the appearance of antibodies in subjects who were initially seronegative (S-) (i.e. with concentrations < cut-off value) or at least doubling of pre-vaccination antibody concentrations in subjects who were initially seropositive (S+) (i.e. with concentrations > cut-off value).
Number of Subjects With Any Solicited Local Symptoms [ Time Frame: During the 4-day (Days 0-3) follow-up period after the booster vaccination ]
Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade.
Number of Subjects With Any Solicited General Symptoms [ Time Frame: During the 4-day (Days 0-3) follow-up period after the booster vaccination ]
Assessed solicited general symptoms were drowsiness, fever [defined as rectal temperature equal to or above (≥) 38.0 degrees Celsius (°C)], irritability and loss of appetite. Any = occurrence of the symptom regardless of intensity grade.
Number of Subjects With Unsolicited Adverse Events (AEs) [ Time Frame: During the 31-day (Day 0-30) follow-up period after the booster vaccination ]
An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination.
Number of Subjects With Serious Adverse Events (SAEs) [ Time Frame: From Month 0 to Month 1, during the entire study period ]
Assessed SAEs include medical occurrences that result in death, are life-threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.
Number of Subjects Reporting Concomitant Medications [ Time Frame: During the 4-day (Days 0-3) follow-up period after the booster vaccination ]

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information

Ages Eligible for Study:	16 Months to 20 Months (Child)
Sexes Eligible for Study:	All
Accepts Healthy Volunteers:	Yes

Criteria

Inclusion Criteria:

Subjects for whom the investigator believes that their parents/guardians can and will comply with the requirements of the protocol
Subjects must have completed the full three-dose primary vaccination course with one of the formulations of the DTPa-HBV-IPV/Hib vaccine in primary study 106786.
A male or female between, and including, 16 and 20 months of age at the time of booster vaccination.
Written informed consent obtained from the parent or guardian of the subject
Healthy subjects as established by medical history and clinical examination before entering into the study.

Exclusion Criteria:

Use of any investigational or non-registered product (drug or vaccine) other than the study vaccine within 30 days preceding the booster dose of study vaccine, or planned use during the study period.
Chronic administration of immunosuppressants or other immune-modifying drugs within six months prior to the booster vaccine dose.
Participation in another clinical study, between the primary study 106786 and the present booster study, or at any time during the study, in which the subject has been or will be exposed to an investigational or a non-investigational product.
Planned administration or administration of a vaccine not foreseen by the study protocol during the period starting 30 days before the administration of the booster dose and ending 30 days after the booster dose.
Evidence of previous diphtheria, tetanus, pertussis, polio, hepatitis B and/or Hib booster vaccination or disease since the conclusion visit of study 106786.
Any confirmed or suspected immunosuppressive or immunodeficient condition, based on physical examination.
History of allergic disease or reactions likely to be exacerbated by any component of the vaccines.
Acute disease at the time of enrolment.
Administration of immunoglobulins and/or any blood products within the three months preceding the booster dose or planned administration during the study period.

Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00627458

Locations

Layout table for location information

Finland
GSK Investigational Site
Jarvenpaa, Finland, 04400
GSK Investigational Site
Oulu, Finland, 90220
GSK Investigational Site
Pori, Finland, 28100
GSK Investigational Site
Tampere, Finland, 33100
GSK Investigational Site
Turku, Finland, 20520
GSK Investigational Site
Vantaa, Finland, 01300

Sponsors and Collaborators

GlaxoSmithKline

Investigators

Layout table for investigator information

Study Director:	GSK Clinical Trials	GlaxoSmithKline

More Information

Additional Information:

Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research. This link exits the ClinicalTrials.gov site